メインビジュアル

東京大学医学部附属病院 腎臓・内分泌内科

〒113-8655 東京都文京区本郷7-3-1

お問い合わせ03-3815-5411（代表）

MENU

内分泌・骨ミネラル代謝研究 g01_endocrinology

       

責任者

伊東 伸朗（Nobuaki Ito）

メンバー

特任准教授:伊東 伸朗（Nobuaki Ito)（難治性骨疾患治療開発講座）
助教:星野良朋（Yoshitomo Hoshino）
ポスドク:日髙尚子（Naoko Hidaka）
ポスドク:木村聡一郎（Soichiro Kimura）
大学院生:入江航生（Koki Irie）
大学院生:足立夏帆（Natsuho Adachi）(小児科)
大学院生:古川滉一朗（Koichiro Furukawa）
実験助手:尾崎 知子（Tomoko Ozaki)
留学中 加藤創生（Hajime Kato）（Yale School of Medicine）

 

研究室のより詳細な紹介は下記HPをご参照ください
難治性骨疾患治療開発講座HP (問合わせ、ピロリン酸、FGF23測定依頼）

研究内容

当研究室は臨床では内分泌疾患全般を診療していますが、特に骨粗鬆症や副甲状腺疾患、くる病・骨軟化症、悪性腫瘍に伴う高カルシウム血症や先天性骨代謝疾患などの骨ミネラル代謝疾患を専門的に診療しています。

① 骨粗鬆症

骨粗鬆症に関しては、骨折のリスクや骨折後に寝たきりとなるなどといった事後の影響を考えると、心筋梗塞や脳梗塞などの発症リスクとなる生活習慣病(高血圧や脂質異常症、糖尿病など)と同様に予防医学の観点で重要な疾患であると認知されてきています。骨粗鬆症は従来治療法が限られていましたが、近年様々な機序の製剤が開発されています。今後も新規の治療薬が保険適応となる予定であり、より患者さんの病態に応じたテーラーメード医療が可能な分野となってきています。

② 続発性骨粗鬆症と骨粗鬆症類縁疾患

内分泌内科では原発性副甲状腺機能亢進症やクッシング症候群といった続発性に骨粗鬆症を起こす様々な疾患や、くる病・骨軟化症、多発性骨髄腫などの骨粗鬆症類縁疾患の鑑 別診断を徹底することで、骨粗鬆症の原因となる重要な疾患を見逃さないようにしています。また骨粗鬆症のプライマリケアを担当することの多い整形外科医や一般内科医、および骨粗鬆症患者さんを対象として、比較的頻度の高い原発性副甲状腺機能亢進症、ビタミンD欠乏症性骨軟化症や、以下に記載しているFGF23関連低リン血症性くる病・骨軟化症や低ホスファターゼ症をといった続発性骨粗鬆症、骨粗鬆症類縁疾患が見逃されてしまう症例が減るように全国的な疾患啓発活動に注力しています。

③ FGF23 関連低リン血症性くる病・骨軟化症

臨床研究、基礎研究では、カルシウム感知受容体(CaSR)の遺伝子異常による新たな病態の解明を行ってきました。近年では腫瘍性骨軟化症(TIO)、X染色体連鎖性低リン血症性くる病(XLH)といった低リン血症性くる病・骨軟化症の原因となる血中のリン濃度調節ホルモン:FGF23をクローニングすると共に、その測定法を開発いたしました。またFGF23の測定が、骨ミネラル代謝異常症の診断に有用であることを示しました。またFGF23関連低リン血症性くる病・骨軟化症に対する抗FGF23抗体医薬が国内でも承認され、本症の治療法を画期的に飛躍させることが出来ました。
低リン血症性くる病・骨軟化症の鑑別診断においては、現在FGF23測定が保険適用となっていますが診断目的に原則1回のみの測定に限られています。医療機関等からの要請に応じて研究目的でのFGF23測定や遺伝性低リン血症性くる病・骨軟化症の遺伝子診断（FGF23、PHEX、DMP1、ENPP1、FAM20C、PTHR1、FGFR1-4、NF1、SLC34A1、SLC34A3遺伝子、SLC9A3R1、CLCN5、OCRL、CYP2R1、HNRNPC、CYP3A4など）を行っています(下記グループのHPをご参照ください)。
FGF23産生腫瘍が原因となる腫瘍性骨軟化症では、腫瘍の切除が根治治療となりますが、原因腫瘍のサイズが小さく局在診断が困難である事が多いため、当グループでは既に保険適応となっているソマトスタチン受容体シンチグラフィとともに、機能的局在診断の補助となる全身でのFGF23静脈サンプリングを特定臨床研究として施行しています。該当するご症例がおられましたら是非ご紹介ください。
上記臨床研究から得られる知見をもとに、基礎研究として2019年にはそれまでに明らかとされていなかった生体内での血中リン濃度感知機構（PiSR）において、FGFRが中心的な役割を担うことを徳島大学との共同研究で明らかとしました。今後はこのFGFRを介した生体のリン感知メカニズムのより詳細なメカニズムの解明や、FGFRのシグナル異常が関与する病態などについて更に検討を進めていきたいと考えています。

④ 低ホスファターゼ症

低リン血性くる病・骨軟化症と類似した疾患で、アルカリホスファターゼという酵素の異常により骨の局所でのリン濃度の低下が起こることでくる病・骨軟化症と同様の病態を呈する低ホスファターゼ症(HPP)という疾患があります。新生児や乳児期に発症する症例は非常に重篤で、肋骨の形成不全などから出生後に呼吸困難となり生命の危機に瀕する病型です。一方で、小児期や成人期まで明らかな症状を呈さずに、それ以降、偽骨折(強い運動負荷を伴わずに生じるヒビのような骨折)や通常の骨折を繰り返す比較的症状が軽度なHPPも存在しています。そのほとんどの症例が骨粗鬆症として、HPPの場合にはむしろ骨折リスクを増加させてしまうビスホスフォネートなどの骨吸収抑制薬での加療が行われていると考えられます。2015年に本症に対する酵素補充療法が保険適用となったこともあり、骨折を頻回に繰り返す成人例などから本症を、低ALP血症を手掛かりとして正しく診断することの重要性を啓発しております。HPPに関してもALPL遺伝子変異の遺伝子診断を承っておりますので、疑わしい症例がおられましたらご紹介頂けますと幸いです。

⑤ その他の骨代謝疾患

このほかにも骨形成不全症や軟骨無形成症、大理石骨病といった様々な遺伝性の骨代謝疾患の小児科からの移行や骨パジェット病、後縦靭帯骨化症などの病態解明のためのご紹介を受け入れております。また先天性もしくは後天性で原因が明らかでない骨代謝疾患などの原因を次世代シークエンサーなどの機器を利用して解明する検討も行っておりますので、診断に難渋する症例がございましたらご連絡頂けますと幸いです。

お知らせ

● 東京大学医学部附属病院で内分泌内科を受診された患者さんへ　研究課題「内分泌疾患、糖代謝、骨代謝疾患、腎疾患、悪性腫瘍性疾患、自己免疫疾患における保険未収載血中、尿中、その他体液の関連因子の検討」および研究課題「希少な内分泌代謝疾患、糖代謝異常症、骨代謝異常症、腎疾患の病因、病態解析のための次世代シークエンサーの利用」にご参加頂いている患者さんへ

● 東京大学医学部附属病院で内分泌内科を受診された患者さんへ　研究課題「内分泌疾患、糖代謝、骨代謝疾患、腎疾患、悪性腫瘍性疾患における保険未収載血中、尿中、その他体液の関連因子の検討」および研究課題「希少な内分泌代謝疾患、糖代謝異常症、骨代謝異常症、腎疾患の病因、病態解析のための次世代シークエンサーの利用」にご参加頂いている後縦靭帯骨化症患者さん及び変形性関節症患者さんへ

● 東京大学医学部附属病院で腫瘍性骨軟化症の原因腫瘍切除術を施行された患者さん、ならびに東京大学医学部附属病院整形外科・脊椎外科で研究にご参加されている患者さんへ

● 当科にて骨・カルシウム代謝異常症でご加療中の方へ

● 悪性腫瘍の骨転移に対するランマーク投与の安全性についての検討

● 当院にて運動器の病気でご加療中の方へ

連絡先

当研究室に興味のある方、FGF23 関連の臨床情報についてのお問い合わせ、FGF23 測定 依頼、研究の御相談、また低リン血症性くる病・骨軟化症患者さんからのお問い合わせ、 御相談を受け付けています。お気軽にご連絡ください。

難治性骨疾患治療開発講座HP (問合わせ、ピロリン酸、FGF23測定依頼）

ともに Ito N, et al. Clin Rev Bone Miner Metab 2014より

2026年3月時点業績

  1. Hoshino Y, Ito N. Autoimmune osteomalacia: a novel FGF23-related hypophosphatemic osteomalacia. J Bone Miner Metab. 2026 Feb 14. doi: 10.1007/s00774-026-01697-0. Epub ahead of print. PMID: 41691126.
  2. Srivastava S, Kato H, von Kroge S, Weise K, Stabach P, Lopez SG, O’Brien K, Lester ER, Kim H, Ishaq T, Dammen-Brower K, Schinke T, Kimura S, Miyahara J, Doi T, Oshima Y, Yarema KJ, Carpenter TO, Sabbagh Y, Tommasini SM, Ito N, Oheim R, Braddock DT. The prevalence of ENPP1 deficiency in humans with OPLL and the preclinical efficacy of ENPP1 enzyme therapy in OPLL mice. J Bone Miner Res. 2025 Nov 18:zjaf168. doi: 10.1093/jbmr/zjaf168. Epub ahead of print. PMID: 41251406.
  3. Fujiwara K, Kabata D, Kawai R, Kang HG, Namba N, Ito N, Shintani A, Fukumoto S, Ozono K, Michigami T. Distribution of blood pressure and its positive association with body mass index standard deviation score in pediatric patients with X-linked hypophosphatemia: a sub-group analysis from the SUNFLOWER observational study. Endocr J. 2025 Oct 4. doi: 10.1507/endocrj.EJ25-0179. Epub ahead of print. PMID: 41047346.
  4. Irie K, Kato H, Adachi N, Kimura S, Hoshino Y, Hidaka N, Tanaka S, Nangaku M, Saito T, Makita N, Ito N. PHEX protein in the parathyroid gland contributes to phosphate sensing. J Clin Endocrinol Metab. 2025 Jun 13:dgaf357. doi: 10.1210/clinem/dgaf357. Epub ahead of print. PMID: 40512822.
  5. Ito N, Fukumoto S. Tumor-induced rickets/osteomalacia (TIO): diagnostic pitfalls and therapeutic options. J Bone Miner Res. 2025 Mar 28:zjaf047. doi: 10.1093/jbmr/zjaf047. Epub ahead of print. PMID: 40156290.
  6. Ito N, Kang HG, Michigami T, Namba N, Kubota T, Shintani A, Kawai R, Kabata D, Ishii H, Nishida Y, Fukumoto S, Ozono K. Prevalence of Comorbid Hyperparathyroidism and Its Association with Renal Dysfunction in Asian Patients with X-Linked Hypophosphatemic Rickets/Osteomalacia. Calcif Tissue Int. 2025 Mar 12;116(1):50. doi: 10.1007/s00223-025-01359-9. PMID: 40074938.
  7. Hidaka N, Oyama Y, Koga M, Kondo N, Yasunaga Y, Shimakura T, Yamamoto N, Takahashi HE, Iwafuchi Y, Watanabe S, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Kobayashi H, Tanaka T, Ushiku T, Nangaku M, Tanaka S, Makita N, Saito T, Ito N. Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone. JBMR Plus. 2025 Jan 16;9(3):ziaf010. doi: 10.1093/jbmrpl/ziaf010. PMID: 39963340; PMCID: PMC11831984.
  8. Hoshino Y, Okamoto K, Ogawa T, Kato H, Irie K, Watanabe S, Kimura S, Hidaka N, Kinoshita Y, Kobayashi H, Hagiwara D, Kogawa M, Takayanagi H, Tanaka S, Nangaku M, Makita N, Burbelo PD, Saito T, Ito N. Acquired Osteomalacia Associated with Autoantibodies against PHEX. N Engl J Med. 2025 Jan 30;392(5):513-515. doi: 10.1056/NEJMc2405746. PMID: 39879599.
  9. Yoshida H, Murakami T, Ogawa A, Sunouchi T, Hidaka N, Ito N, Murakami H, Kawasaki H, Akiyama T, Nakajima K, Yabe D, Yamamoto T. Adult hypophosphatasia presenting with recurrent acute joint pain. Endocrinol Diabetes Metab Case Rep. 2025 Jan 27;2025(1):e240121. doi: 10.1530/EDM-24-0121. PMID: 39868560.
  10. Kato H, Ishihara Y, Ohata Y, Irie K, Watanabe S, Kimura S, Hoshino Y, Hidaka N, Kinoshita Y, Taniguchi Y, Kobayashi H, Braddock DT, Kubota T, Ozono K, Nangaku M, Makita N, Ito N. Effect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia. J Endocr Soc. 2024 Oct 22;8(12):bvae184. doi: 10.1210/jendso/bvae184. PMID: 39498416; PMCID: PMC11532897.
  11. Namba N, Ito N, Michigami T, Kang HG, Kubota T, Miyazaki O, Shintani A, Kabata D, Nishida Y, Fukumoto S, Ozono K. Impact of X-linked hypophosphatemic rickets/osteomalacia on health and quality of life: baseline data from the SUNFLOWER longitudinal, observational cohort study. JBMR Plus. 2024 Sep 10;8(11):ziae118. doi: 10.1093/jbmrpl/ziae118. PMID: 39399158; PMCID: PMC11470975.
  12. Michigami T, Kang HG, Namba N, Ito N, Kubota T, Shintani A, Kabata D, Kanematsu M, Nishida Y, Fukumoto S, Ozono K. Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study. JBMR Plus. 2024 Jun 10;8(8):ziae079. doi: 10.1093/jbmrpl/ziae079. PMID: 39015507; PMCID: PMC11250265.
  13. Kimura S, Sunouchi T, Watanabe S, Hoshino Y, Hidaka N, Kato H, Takeda S, Nangaku M, Makita N, Azuma K, Kojima T, Matsubara T, Saito T, Ito N. Latent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study. Osteoporos Int. 2024 Sep;35(9):1633-1643. doi: 10.1007/s00198-024-07168-4. Epub 2024 Jul 1. PMID: 38951164; PMCID: PMC11364693.
  14. Hidaka N, Inoue K, Kato H, Hoshino Y, Koga M, Kinoshita Y, Takashi Y, Makita N, Fukumoto S, Nangaku M, Ito N. FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis. JACC Adv. 2023 Dec 9;3(1):100747. doi: 10.1016/j.jacadv.2023.100747. PMID: 38939808; PMCID: PMC11198284.
  15. Kato H, Kitamoto T, Kimura S, Sunouchi T, Hoshino Y, Hidaka N, Tsurutani Y, Ito N, Makita N, Nishikawa T, Nangaku M, Inoue K. Cardiovascular Outcomes of KCNJ5 Mutated Aldosterone-Producing Adenoma: A Systematic Review. Endocr Pract. 2024 Jul;30(7):670-678. doi: 10.1016/j.eprac.2024.04.007. Epub 2024 Apr 22. PMID: 38657793.
  16. Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S, Tanaka I, Kitajima Y, Kubota T, Ebina K, Takashi Y, Inoue R, Yamauchi M, Okubo N, Ueno M, Ohata Y, Ito N, Ozono K, Nakayama H, Terauchi M, Tanaka S, Fukumoto S. The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab. 2024 Mar;42(2):143-154. doi: 10.1007/s00774-024-01502-w. Epub 2024 Mar 28. PMID: 38538869; PMCID: PMC10982086.
  17. Tanaka H, Tamura M, Muto M, Kinoshita Y, Ito N, Oka A, Kitanaka S. A novel pathogenic variant in fibroblast growth factor 23 outside the furin-recognizing RXXR motif in an autosomal dominant hypophosphatemic rickets patient. Horm Res Paediatr. 2024 Mar 15. doi: 10.1159/000538388. Epub ahead of print. PMID: 38493780.
  18. Ito N, Hidaka N, Kato H. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia. Endocrinol Metab (Seoul). 2024 Apr;39(2):255-261. doi: 10.3803/EnM.2023.1908. Epub 2024 Mar 11. PMID: 38467164; PMCID: PMC11066443.
  19. Okajima K, Kobayashi H, Ito N, Kato H, Ishibashi Y, Zhang L, Tsuda Y, Tanaka S. Extended curettage for tumour-induced osteomalacia in the bone. Jpn J Clin Oncol. 2024 Apr 6;54(4):463-470. doi: 10.1093/jjco/hyad180. PMID: 38266040.
  20. Tsuda Y, Yasunaga Y, Abe M, Hoshi K, Ito N, Kondo K, Okajima K, Zhang L, Kato H, Hidaka N, Tanaka S, Kobayashi H. Surgical and biochemical outcomes of phosphaturic mesenchymal tumors causing tumor-induced osteomalacia in the head and neck region. Oral and Maxillofacial Surgery Cases. 2023; 9(4):100335. doi: 10.1016/j.omsc.2023.100335.
  21. Hidaka N, Murata H, Tachikawa K, Osaki K, Sekiyama T, Kinoshita Y, Kato H, Hoshino Y, Kimura S, Sunouchi T, Watanabe S, Nangaku M, Makita N, Michigami T, Ito N. The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult-Onset Hypophosphatasia. JBMR Plus. 2023 Nov 20;7(12):e10842. doi: 10.1002/jbm4.10842. PMID: 38130758; PMCID: PMC10731098.
  22. Ito N, Hidaka N, Kato H. The pathophysiology of hypophosphatemia. Best Pract Res Clin Endocrinol Metab. 2024 Mar;38(2):101851. doi: 10.1016/j.beem.2023.101851. Epub 2023 Nov 30. PMID: 38087658.
  23. Qian C, Ito N, Tsuji K, Sato S, Kikuchi K, Yoshii T, Miyata T, Asou Y. A PAI-1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D-resistant rickets model mouse. FEBS Open Bio. 2024 Feb;14(2):290-299. doi: 10.1002/2211-5463.13745. Epub 2023 Dec 25. PMID: 38050660; PMCID: PMC10839342.
  24. Arima T, Sugimoto K, Taniwaki T, Maeda K, Shibata Y, Tateyama M, Karasugi T, Tokunaga T, Sueyoshi T, Hisanaga S, Masuda T, Uehara Y, Yugami M, Matsushita K, Yonemitsu R, Kawakami J, Yoshimura N, Tanimura S, Kato H, Ito N, Inoue K, Bando K, Nakamura T, Miyamoto T. Cartilage tissues regulate systemic aging via ectonucleotide pyrophosphatase/phosphodiesterase 1 in mice. J Biol Chem. 2024 Jan;300(1):105512. doi: 10.1016/j.jbc.2023.105512. Epub 2023 Nov 30. PMID: 38042486; PMCID: PMC10777000.
  25. Arai M, Ochi H, Sunamura S, Ito N, Nangaku M, Takeda S, Sato S. A Novel Long Noncoding RNA in Osteocytes Regulates Bone Formation through the Wnt/β-Catenin Signaling Pathway. Int J Mol Sci. 2023 Sep 4;24(17):13633. doi: 10.3390/ijms241713633. PMID: 37686441.
  26. Kato H, Braddock DT, Ito N. Genetics of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Spinal Ligaments. Curr Osteoporos Rep. 2023 Oct;21(5):552-566. doi: 10.1007/s11914-023-00814-6. Epub 2023 Aug 2. PMID: 37530996; PMCID: PMC10543536.
  27. Kato H, Kimura S, Taguchi M, Sunouchi T, Hoshino Y, Hidaka N, Edvige Foligno N, Koga M, Manaka K, Tamiya H, Kawakami M, Kage H, Yasunaga Y, Nangaku M, Makita N, Ito N. FGF23-related hypophosphatemia in a patient with small cell lung cancer: a case report and literature review. Endocr J. 2023 Oct 30;70(10):1005-1013. doi: 10.1507/endocrj.EJ23-0086. Epub 2023 Jul 20. PMID: 37468265.
  28. Hoshino Y, Manaka K, Sato J, Asatsuma Y, Horikoshi H, Takeuchi M, Ito N, Fujita M, Yasunaga M, Matsuda K, Honda A, Maki H, Masamoto Y, Kurokawa M, Nangaku M, Makita N. Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report. BMC Endocr Disord. 2023 Jun 5;23(1):128. doi: 10.1186/s12902-023-01384-5. PMID: 37277771.
  29. Kobayashi H, Ito N, Nakai Y, Katoh H, Okajima K, Zhang L, Tsuda Y, Tanaka S. Patterns of symptoms and insufficiency fractures in patients with tumour-induced osteomalacia. Bone Joint J. 2023 May 1;105-B(5):568-574. doi: 10.1302/0301-620X.105B5.BJJ-2022-1206.R2. PMID: 37121579.
  30. Kato H, Miyazaki H, Kimura T, Hoshino Y, Hidaka N, Koga M, Nangaku M, Makita N, Ito N. Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia. Bone Rep. 2023 Feb 2;18:101659. doi: 10.1016/j.bonr.2023.101659. PMID: 36817167; PMCID: PMC9932357.
  31. Ramos P, Larson B, Ashrafzadeh-Kian S, Ito N, Kato H, Bornhorst JA, Algeciras-Schimnich A. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders. Endocr Pract. 2023 Mar;29(3):193-198. doi: 10.1016/j.eprac.2023.01.003. Epub 2023 Jan 7. PMID: 36627024.
  32. Kato H, Koga M, Kinoshita Y, Hidaka N, Hoshino Y, Takashi Y, Arai M, Kobayashi H, Katsura M, Nakamoto Y, Makise N, Ushiku T, Hoshi K, Nangaku M, Makita N, Fukumoto S, Ito N. Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors. J Endocr Soc. 2022 Nov 24;7(2):bvac181. doi: 10.1210/jendso/bvac181. PMID: 36540156; PMCID: PMC9757682.
  33. Kato H, Okawa R, Ogasawara T, Hoshino Y, Hidaka N, Koga M, Kinoshita Y, Kobayashi H, Taniguchi Y, Fukumoto S, Nangaku M, Makita N, Hoshi K, Nakano K, Ito N. Effect of Conventional Treatment on Dental Complications and Ectopic Ossifications Among 30 Adults With XLH. J Clin Endocrinol Metab. 2023 May 17;108(6):1405-1414. doi: 10.1210/clinem/dgac732. PMID: 36524341.
  34. Hoshino Y, Hidaka N, Kato H, Koga M, Taniguchi Y, Kobayashi H, Nangaku M, Makita N, Ito N. Incidence of ossification of the spinal ligaments in acromegaly patients. Bone Rep. 2022 Oct 17;17:101628. doi: 10.1016/j.bonr.2022.101628. PMID: 36299702; PMCID: PMC9589022.
  35. Ashrafzadeh-Kian SL, Ito N, Srivastava T, Garg U, Kato H, Algeciras-Schimnich A, Bornhorst JA. The effect of burosumab on intact and C-terminal FGF23 measurements. Clin Endocrinol (Oxf). 2023 Aug;99(2):152-157. doi: 10.1111/cen.14832. Epub 2022 Oct 31. PMID: 36263608.
  36. Kato H, Hoshino Y, Hidaka N, Ito N, Makita N, Nangaku M, Inoue K. Machine Learning-Based Prediction of Elevated PTH Levels Among the US General Population. J Clin Endocrinol Metab. 2022 Nov 25;107(12):3222-3230. doi: 10.1210/clinem/dgac544. Erratum in: J Clin Endocrinol Metab. 2022 Dec 01. PMID: 36125184; PMCID: PMC9693802.
  37. Brandi ML, Jan de Beur S, Briot K, Carpenter T, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Imel EA, Ing SW, Insogna K, Ito N, Javaid K, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Portale A, Ralston SH, Tanaka H, Weber TJ, Yoo HW, Sun W, Williams A, Nixon A, Takeuchi Y. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcif Tissue Int. 2022 Oct;111(4):409-418. doi: 10.1007/s00223-022-01006-7. Epub 2022 Aug 4. PMID: 35927518.
  38. Hidaka N, Koga M, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Makita N, Nangaku M, Horiguchi K, Furukawa Y, Ohnaka K, Inagaki K, Nakagawa A, Suzuki A, Takeuchi Y, Fukumoto S, Nakatani F, Ito N. Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance. J Bone Miner Res. 2022 Aug;37(8):1479-1488. doi: 10.1002/jbmr.4620. Epub 2022 Jul 1. PMID: 35690913.
  39. Hofstaetter JG, Atkins GJ, Kato H, Kogawa M, Blouin S, Misof BM, Roschger P, Evdokiou A, Yang D, Solomon LB, Findlay DM, Ito N. A Mild Case of Autosomal Recessive Osteopetrosis Masquerading as the Dominant Form Involving Homozygous Deep Intronic Variations in the CLCN7 Gene. Calcif Tissue Int. 2022 Oct;111(4):430-444. doi: 10.1007/s00223-022-00988-8. Epub 2022 May 26. PMID: 35618777; PMCID: PMC9474465.
  40. Kato H, Ansh AJ, Lester ER, Kinoshita Y, Hidaka N, Hoshino Y, Koga M, Taniguchi Y, Uchida T, Yamaguchi H, Niida Y, Nakazato M, Nangaku M, Makita N, Takamura T, Saito T, Braddock DT, Ito N. Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early-Onset Osteoporosis. J Bone Miner Res. 2022 Jun;37(6):1125-1135. doi: 10.1002/jbmr.4550. Epub 2022 Apr 11. PMID: 35340077; PMCID: PMC9177665.
  41. Ito N. Adult Presentation of X-Linked Hypophosphatemia. Endocrines. 2022; 3(3):375-390. doi: 10.3390/endocrines3030030.
  42. Kato H, Hidaka N, Koga M, Kinoshita Y, Makita N, Nangaku M, Ito N. Radiological evaluation of pseudofracture after the administration of asfotase alfa in an adult with benign prenatal hypophosphatasia: A case report. Bone Rep. 2021 Dec 29;16:101163. doi: 10.1016/j.bonr.2021.101163. PMID: 35024386; PMCID: PMC8728307.
  43. Hidaka N, Kato H, Koga M, Katsura M, Oyama Y, Kinoshita Y, Fukumoto S, Makita N, Nangaku M, Ito N. Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption. Bone Rep. 2021 Oct 16;15:101144. doi: 10.1016/j.bonr.2021.101144. PMID: 34901334; PMCID: PMC8640868.
  44. Kato H, Hidaka N, Koga M, Kinoshita Y, Nangaku M, Makita N, Ito N. Altered Thyroid Function Tests Observed in Hypophosphatasia Patients Treated with Asfotase Alfa. Int J Endocrinol. 2021 Oct 28;2021:5492267. doi: 10.1155/2021/5492267. PMID: 34745256; PMCID: PMC8568557.
  45. Ito N, Kang HG, Nishida Y, Evins A, Skrinar A, Cheong HI. Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey. Endocr J. 2022 Apr 28;69(4):373-383. doi: 10.1507/endocrj.EJ21-0386. Epub 2021 Nov 2. PMID: 34732603.
  46. Kato H, Ito N, Makita N, Nangaku M, Leung AM, Inoue K. Association of Serum Parathyroid Hormone Levels With All-Cause and Cause-Specific Mortality Among U.S. Adults. Endocr Pract. 2022 Jan;28(1):70-76. doi: 10.1016/j.eprac.2021.09.005. Epub 2021 Sep 23. PMID: 34563702.
  47. Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. 2021 Sep;7(3):e001714. doi: 10.1136/rmdopen-2021-001714. PMID: 34548383.
  48. Koga M, Kinoshita Y, Kato H, Kobayashi H, Shinoda Y, Nangaku M, Makita N, Dahir KM, Ito N. Massive calcification around large joints in a patient subsequently diagnosed with adult-onset hypophosphatasia. Osteoporos Int. 2022 Feb;33(2):505-509. doi: 10.1007/s00198-021-06145-5. Epub 2021 Sep 8. PMID: 34494146.
  49. Kato H, Hidaka N, Koga M, Ogawa N, Takahashi S, Miyazaki H, Nangaku M, Makita N, Ito N. Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system. J Bone Miner Metab. 2022 Jan;40(1):101-108. doi: 10.1007/s00774-021-01258-7. Epub 2021 Aug 5. PMID: 34351500.
  50. Ito N, Kubota T, Kitanaka S, Fujiwara I, Adachi M, Takeuchi Y, Yamagami H, Kimura T, Shinoda T, Minagawa M, Okazaki R, Ozono K, Seino Y, Fukumoto S. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23. J Bone Miner Metab. 2021 Nov;39(6):1066-1075. doi: 10.1007/s00774-021-01250-1. Epub 2021 Jul 13. PMID: 34255195.
  51. Kinoshita Y, Mohamed FF, Amadeu de Oliveira F, Narisawa S, Miyake K, Foster BL, Millán JL. Gene Therapy Using Adeno-Associated Virus Serotype 8 Encoding TNAP-D10 Improves the Skeletal and Dentoalveolar Phenotypes in Alpl-/- Mice. J Bone Miner Res. 2021 Sep;36(9):1835-1849. doi: 10.1002/jbmr.4382. Epub 2021 Jun 15. PMID: 34076297; PMCID: PMC8446309.
  52. Kato H, Koga M, Kinoshita Y, Taniguchi Y, Kobayashi H, Fukumoto S, Nangaku M, Makita N, Ito N. Incidence of complications in 25 adult patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3682-e3692. doi: 10.1210/clinem/dgab282. PMID: 33912912.
  53. Ito N, Prideaux M, Wijenayaka AR, Yang D, Ormsby RT, Bonewald LF, Atkins GJ. Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23. Calcif Tissue Int. 2021 Jul;109(1):66-76. doi: 10.1007/s00223-021-00823-6. Epub 2021 Feb 22. PMID: 33616712.
  54. Kato H, Koga M, Kobayashi H, Maki H, Ikemura M, Kurokawa M, Nangaku M, Makita N, Ito N. Primary bone adult T cell lymphoma with multiple skeletal lesions and debilitating painful osteolysis: a case report. Osteoporos Int. 2021 May;32(5):1013-1017. doi: 10.1007/s00198-020-05720-6. Epub 2020 Oct 31. PMID: 33128574.
  55. Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia. J Bone Miner Res. 2021 Feb;36(2):262-270. doi: 10.1002/jbmr.4184. Epub 2020 Nov 4. PMID: 32967046.
  56. Kobayashi H, Makise N, Ito N, Koga M, Zhang L, Ishibashi Y, Ikegami M, Shinoda Y, Akiyama T, Ushiku T, Tanaka S. Surgical margin for phosphaturic mesenchymal tumors in soft tissues: An analysis of the radiological histopathological correlation. J Orthop Sci. 2021 Sep;26(5):870-877. doi: 10.1016/j.jos.2020.07.006. Epub 2020 Aug 11. PMID: 32798110.
  57. Kubota T, Fukumoto S, Cheong HI, Michigami T, Namba N, Ito N, Tokunaga S, Gibbs Y, Ozono K. Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study. BMJ Open. 2020 Jun 29;10(6):e036367. doi: 10.1136/bmjopen-2019-036367. PMID: 32601114.
  58. Ito N, Fukumoto S. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23. Calcif Tissue Int. 2021 Jan;108(1):104-115. doi: 10.1007/s00223-020-00659-6. Epub 2020 Jan 22. PMID: 31965220.
  59. Kobayashi H, Hirai T, Makise N, Ushiku T, Ito N, Koga M, Ikegami M, Shinoda Y, Akiyama T, Tanaka S. Reconstruction Using Frozen Autograft for Disseminated Phosphaturic Mesenchymal Tumor of the Humerus after a Pathological Fracture. Case Rep Orthop. 2019 Sep 4;2019:3015675. doi: 10.1155/2019/3015675. PMID: 31565455.
  60. Sahoo SK, Kushwaha P, Bharti N, Khedgikar V, Trivedi R, Agrawal V, Ahmad N, Zaidi G, Paul L, Ito N, Bhatia E. Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1. Bone. 2019 Dec;129:115055. doi: 10.1016/j.bone.2019.115055. Epub 2019 Aug 30. PMID: 31476437.
  61. Insogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. J Bone Miner Res. 2019 Dec;34(12):2183-2191. doi: 10.1002/jbmr.3843. Epub 2019 Oct 1. PMID: 31369697.
  62. Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int. 2019 Sep;105(3):271-284. doi: 10.1007/s00223-019-00568-3. PMID: 31165191.
  63. Takashi Y, Kosako H, Sawatsubashi S, Kinoshita Y, Ito N, Tsoumpra MK, Nangaku M, Abe M, Matsuhisa M, Kato S, Matsumoto T, Fukumoto S. Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11418-11427. doi: 10.1073/pnas.1815166116. PMID: 31097591.
  64. Manaka K, Sato J, Kinoshita Y, Ito N, Fujita M, Iiri T, Nangaku M, Makita N. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. Endocr J. 2019 Aug 29;66(8):683-689. doi: 10.1507/endocrj.EJ19-0034. Epub 2019 May 16. PMID: 31092749.
  65. Kobayashi H, Makise N, Ushiku T, Ito N, Koga M, Shinoda Y, Tanaka S. Infiltrative nature of tumor-induced osteomalacia lesions in bone: Correlation between radiological and histopathological features. J Orthop Sci. 2019 Sep;24(5):900-905. doi: 10.1016/j.jos.2019.02.005. Epub 2019 Feb 21. PMID: 30797665.
  66. Kinoshita Y, Takashi Y, Ito N, Ikegawa S, Mano H, Ushiku T, Fukayama M, Nangaku M, Fukumoto S. Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO). Bone Rep. 2018 Dec 31;10:100192. doi: 10.1016/j.bonr.2018.100192. PMID: 30627598; PMCID: PMC6321977.
  67. Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO; AXLES 1 Investigators. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. PMID: 29947083.
  68. Kinoshita Y, Fukumoto S. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Endocr Rev. 2018 Jun 1;39(3):274-291. doi: 10.1210/er.2017-00220. PMID: 29381780.
  69. Kobayashi H, Ito N, Akiyama T, Okuma T, Kinoshita Y, Ikegami M, Shinoda Y, Fukumoto S, Tanaka S, Kawano H. Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia. Int Orthop. 2017 Dec;41(12):2597-2603. doi: 10.1007/s00264-017-3610-3. Epub 2017 Aug 23. PMID: 28836028.
  70. Kinoshita Y, Ito N, Makita N, Nangaku M, Fukumoto S. Changes in bone metabolic parameters following oral calcium supplementation in an adult patient with vitamin D-dependent rickets type 2A. Endocr J. 2017 Jun 29;64(6):589-596. doi: 10.1507/endocrj.EJ16-0583. Epub 2017 Mar 31. PMID: 28367941.
  71. Takashi Y, Kinoshita Y, Ito N, Taguchi M, Takahashi M, Egami N, Tajima S, Nangaku M, Fukumoto S. Tumor-induced Osteomalacia Caused by a Parotid Tumor. Intern Med. 2017;56(5):535-539. doi: 10.2169/internalmedicine.56.7565. Epub 2017 Mar 1. PMID: 28250301; PMCID: PMC5399206.
  72. Kobayashi H, Akiyama T, Okuma T, Shinoda Y, Oka H, Ito N, Fukumoto S, Tanaka S, Kawano H. Three-dimensional fluoroscopic navigation-assisted surgery for tumors in patients with tumor-induced osteomalacia in the bones. Comput Assist Surg (Abingdon). 2017 Dec;22(1):14-19. doi: 10.1080/24699322.2017.1282044. PMID: 28081649.
  73. Takashi Y, Kinoshita Y, Hori M, Ito N, Taguchi M, Fukumoto S. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy. Endocr Res. 2017 May;42(2):132-137. doi: 10.1080/07435800.2016.1242604. Epub 2016 Oct 18. PMID: 27754732.
  74. Kinoshita Y, Arai M, Ito N, Takashi Y, Makita N, Nangaku M, Shinoda Y, Fukumoto S. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors. Endocr J. 2016 May 31;63(5):479-84. doi: 10.1507/endocrj.EJ16-0003. Epub 2016 Feb 9. PMID: 26860123.
  75. Hori M, Kinoshita Y, Taguchi M, Fukumoto S. Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. J Bone Miner Metab. 2016 Mar;34(2):132-9. doi: 10.1007/s00774-015-0651-9. Epub 2015 Mar 21. PMID: 25792238.
  76. Tajima S, Takashi Y, Ito N, Fukumoto S, Fukuyama M. ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors. Med Mol Morphol. 2016 Dec;49(4):203-209. doi: 10.1007/s00795-015-0115-2. Epub 2015 Jun 30. PMID: 26122367.
  77. Wijenayaka AR, Yang D, Prideaux M, Ito N, Kogawa M, Anderson PH, Morris HA, Solomon LB, Loots GG, Findlay DM, Atkins GJ. 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion. Mol Cell Endocrinol. 2015 Sep 15;413:157-67. doi: 10.1016/j.mce.2015.06.021. Epub 2015 Jun 23. PMID: 26112182.
  78. Takashi Y, Kinoshita Y, Makita N, Taguchi M, Takahashi K, Nangaku M, Fukumoto S. Rapid Recovery of Hypothalamic-Pituitary Axis after Successful Resection of an ACTH-secreting Neuroendocrine Tumor. Intern Med. 2015;54(17):2201-5. doi: 10.2169/internalmedicine.54.4915. Epub 2015 Sep 1. PMID: 26328647.
  79. Ito N, Wijenayaka AR, Prideaux M, Kogawa M, Ormsby RT, Evdokiou A, Bonewald LF, Findlay DM, Atkins GJ. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol Cell Endocrinol. 2015 Jan 5;399:208-18. doi: 10.1016/j.mce.2014.10.007. Epub 2014 Oct 16. PMID: 25458698.
  80. Nakamura T, Aizawa T, Hoshikawa T, Ozawa H, Ito N, Fukumoto S, Itoi E, Kokubun S. Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine. J Orthop Sci. 2015 Jul;20(4):765-71. doi: 10.1007/s00776-014-0540-4. Epub 2014 Feb 7. PMID: 24504987.
  81. Kinoshita Y, Hori M, Taguchi M, Fukumoto S. Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia. Bone. 2014 Oct;67:145-51. doi: 10.1016/j.bone.2014.07.009. Epub 2014 Jul 12. PMID: 25026495.
  82. Ito N, Peña AS, Perano S, Atkins GJ, Findlay DM, Couper JJ. First Australian report of vitamin D-dependent rickets type I. Med J Aust. 2014 Oct 6;201(7):420-1. doi: 10.5694/mja13.00220. PMID: 25296067.
  83. Kinoshita Y, Hori M, Taguchi M, Watanabe S, Fukumoto S. Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia. J Clin Endocrinol Metab. 2014 Feb;99(2):E363-8. doi: 10.1210/jc.2013-3430. Epub 2013 Dec 2. PMID: 24297799.
  84. Ito N, Findlay DM, Atkins GJ. Osteocyte Communication with the Kidney Via the Production of FGF23: Remote Control of Phosphate Homeostasis. Clin Rev Bone Miner Metab. 2014; 12: 44-58. doi: 10.1007/s12018-014-9155-8.
  85. Ito N, Findlay DM, Anderson PH, Bonewald LF, Atkins GJ. Extracellular phosphate modulates the effect of 1α,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J Steroid Biochem Mol Biol. 2013 Jul;136:183-6. doi: 10.1016/j.jsbmb.2012.09.029. Epub 2012 Oct 9. PMID: 23064198.
  86. Kinoshita Y, Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, Fukumoto S, Fujita T. Mutational analysis of patients with FGF23-related hypophosphatemic rickets. Eur J Endocrinol. 2012 Aug;167(2):165-72. doi: 10.1530/EJE-12-0071. Epub 2012 May 10. PMID: 22577109.
  87. Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K, Yamada S, Takeuchi Y. Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur J Endocrinol. 2011 Apr;164(4):467-73. doi: 10.1530/EJE-10-1096. Epub 2011 Feb 1. PMID: 21285083.
  88. Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S, Fujita T. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med. 2010 Oct;268(4):390-4. doi: 10.1111/j.1365-2796.2010.02262.x. PMID: 20698924.
  89. Sakurai-Chin C, Ito N, Taguchi M, Miyakawa M, Takeshita A, Takeuchi Y. Hypoglycemic coma in a patient with anorexia nervosa coincident with acute exacerbation of liver injury induced by oral intake of nutrients. Intern Med. 2010;49(15):1553-6. doi: 10.2169/internalmedicine.49.3373. Epub 2010 Aug 2. PMID: 20686290.
  90. Saito T, Fukumoto S, Ito N, Suzuki H, Igarashi T, Fujita T. A novel mutation in the GATA3 gene of a Japanese patient with PTH-deficient hypoparathyroidism. J Bone Miner Metab. 2009;27(3):386-9. doi: 10.1007/s00774-008-0015-9. Epub 2008 Dec 5. PMID: 19057839.
  91. Saito T, Nishii Y, Yasuda T, Ito N, Suzuki H, Igarashi T, Fukumoto S, Fujita T. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene. Eur J Endocrinol. 2009 Oct;161(4):647-51. doi: 10.1530/EJE-09-0261. Epub 2009 Jul 6. PMID: 19581284.
  92. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009 Oct;45(4):814-6. doi: 10.1016/j.bone.2009.06.017. Epub 2009 Jun 23. PMID: 19555782.
  93. Kinoshita Y, Masuoka K, Miyakoshi S, Taniguchi S, Takeuchi Y. Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy. Bone. 2008 Jan;42(1):226-8. doi: 10.1016/j.bone.2007.09.042. Epub 2007 Sep 22. PMID: 17964238.
  94. Nasu T, Kurisu S, Matsuno S, Tatsumi K, Kakimoto T, Kobayashi M, Nakano Y, Wakasaki H, Furuta H, Nishi M, Sasaki H, Suzuki H, Ito N, Fukumoto S, Nanjo K. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Intern Med. 2008;47(10):957-61. doi: 10.2169/internalmedicine.47.0745. Epub 2008 May 15. PMID: 18480582.
  95. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab. 2007;25(6):419-22. doi: 10.1007/s00774-007-0779-3. Epub 2007 Oct 25. PMID: 17968495.
  96. Kawarazaki H, Shibagaki Y, Shimizu H, Kawarazaki W, Ito N, Ishikawa A, Fukumoto S, Fujita T. Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia. Clin Exp Nephrol. 2007 Sep;11(3):255-257. doi: 10.1007/s10157-007-0489-0. Epub 2007 Sep 28. PMID: 17891358.
  97. Ito N, Fukumoto S, Taguchi M, Takeshita A, Takeuchi Y, Yamada S, Fujita T. Fibroblast growth factor (FGF)23 in patients with acromegaly. Endocr J. 2007 Jun;54(3):481-4. doi: 10.1507/endocrj.k06-217. Epub 2007 Apr 25. PMID: 17457012.
  98. Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I, Navon-Elkan P, Becker-Cohen R, Yamashita T, Araya K, Igarashi T, Fujita T, Fukumoto S. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res. 2007 Feb;22(2):235-42. doi: 10.1359/jbmr.061105. PMID: 17129170.
  99. Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab. 2005;23(6):435-40. doi: 10.1007/s00774-005-0625-4. PMID: 16261449.
  100. Kinoshita Y, Taguchi M, Takeshita A, Miura D, Tomikawa S, Takeuchi Y. 1,25-dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis. J Clin Endocrinol Metab. 2005 Dec;90(12):6727-31. doi: 10.1210/jc.2005-1380. Epub 2005 Sep 13. PMID: 16159932.
  101. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab. 2005 Oct;90(10):5523-7. doi: 10.1210/jc.2005-0301. Epub 2005 Jul 19. PMID: 16030159.

受賞歴

伊東 伸朗（Nobuaki Ito）

  • 2006年　第24回 日本骨代謝学会 IOF-ANZBMS Travel Award
  • 2007年　第20回 内科学会奨励賞
  • 2009年　住友生命社会福祉事業団　海外医学研究助成金
  • 2010年　上原記念生命科学財団 ポストドクトラルフェローシップ
  • 2021年　International award for publishing Excellence in Calcified Tissue International & Musculoskeletal Research
  • 2023年　日本骨代謝学会フロンティア研究者助成
  • 2024年　日本骨代謝学会学術賞
  • 2025年　山口内分泌疾患研究振興財団 奨学寄附金助成
  • 2025年　三井住友海上福祉財団 研究助成
  • 2025年　アステラス病態代謝研究会 研究助成

星野　良朋（Yoshitomo Hoshino）

  • 2021年　第672回 日本内科学会関東地方会指導医賞
  • 2021年　東大病院優秀指導医賞
  • 2023年　第96回日本内分泌学会学術総会「愛・内分泌」賞（優秀演題賞）
  • 2024年　第34回臨床内分泌代謝Update ポスター発表優秀発表賞
  • 2025年  米国内分泌学会（ENDO）C. Wayne Bardin, MD, International Travel Award
  • 2025年　第39回日本内科学会奨励賞
  • 2025年　日本内分泌学会若手研究奨励賞（YIA）
  • 2025年　日本骨代謝学会優秀演題賞
  • 2025年　米国骨代謝学会（ASBMR）Young Investigator Award (YIA)
  • 2025年　米国骨代謝学会（ASBMR）International Meetup Asia-Pacific Award
  • 2025年　持田記念医学薬学振興財団　研究助成

日髙　尚子（Naoko Hidaka）

  • 2015年　第112回日本内科学会総会　医学生・研修医部門　優秀演題賞
  • 2022年　第39回日本骨代謝学会優秀演題賞
  • 2025年　第39回日本内科学会奨励賞
  • 2025年　内藤記念科学振興財団　内藤記念女性研究者研究助成金

木村　聡一郎（Soichiro Kimura）

  • 2023年　第40回日本骨代謝学会 ANZBMS Travel Award
  • 2024年　第41回日本骨代謝学会 ANZBMS Travel Award

入江　航生（Koki Irie）

  • 2023年　第24回日本内分泌学会関東甲信越支部学術集会会長賞

古川　滉一朗（Koichiro Furukawa）

  • 2021年　日本内科学会第670回関東地方会　奨励賞

加藤　創生（Hajime Kato）

  • 2021年　第38回日本骨代謝学会優秀演題賞
  • 2021年　第38回日本骨代謝学会 ECTS Travel Award
  • 2021年　第38回日本骨代謝学会 ANZBMS Travel Award
  • 2022年  第24回日本骨粗鬆症学会　優秀ポスター賞
  • 2022年  国際医学研究振興財団　海外留学助成(辞退)
  • 2022年　内藤記念科学振興財団　海外留学助成金(辞退)
  • 2022年  中富健康科学振興財団　留学助成金(辞退)
  • 2023年  日本学術振興会　海外特別研究員
  • 2023年　ECTS EAST-MEETS-WEST Award
  • 2023年　ASBMR/KSBMR Annual Meeting Young Investigator Travel Grant
  • 2024年　上原記念生命科学財団 若手海外留学支援金
  • 2024年　ASBMR/KSBMR Annual Meeting Young Investigator Travel Grant
  • 2025年　日本骨代謝学会JBMM論文賞